Blog: AstraZeneca announces collaboration on use of artificial intelligence in disease treatment – delawarebusinessnow.com
AstraZeneca and BenevolentAI announced a long-term collaboration to use artificial intelligence and machine learning for the discovery and development of new treatments for chronic kidney disease and idiopathic pulmonary fibrosis (IPF).
Scientists from the two organizations will work to combine AstraZeneca’s genomics, chemistry, and clinical data with BenevolentAI’s target identification platform and biomedical knowledge graph.
Machine learning systematically analyzes data to find connections between facts, and AI-based reasoning is used to come up with previously unknown connections. Together, the companies will interpret the results to understand the underlying mechanisms of these complex diseases and more quickly identify new potential drug targets.
Mene Pangalos, executive vice president and president BioPharmaceuticals R&D, said: “The vast amount of data available to research scientists is growing exponentially each year. By combining AstraZeneca’s disease area expertise and large, diverse datasets with BenevolentAI’s leading AI and machine learning capabilities, we can unlock the potential of this wealth of data to improve our understanding of complex disease biology and identify new targets that could treat debilitating diseases.”
Joanna Shields, CEO, BenevolentAI, said: “Millions of people today suffer from diseases that have no effective treatment. The future of drug discovery and development lies in bridging the gap between AI, data, and biology. We are thrilled to be joining forces with AstraZeneca to develop new insights and identify promising new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.”
CKD and IPF are complex diseases in which the underlying disease biology is poorly understood. This disease complexity requires the interrogation of vast, rich datasets